Role of taxanes in chemotherapy-related cognitive impairment: A prospective longitudinal study

Cerulla, Noemí; Arcusa, Àngels; Navarro, J. Blas; Garolera, Maite; Enero, Cristina; Chico, Gloria; Fernández-Morales, L.A.

doi:10.1007/s10549-017-4240-6

Cited by 27 publications

(27 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The primary reason is that chemotherapy regimens often differ not only in the types of medications received but also the duration of treatment and number of cycles. Studies have shown that anthracyclines, taxanes, and cumulative chemotherapy exposure are associated with poorer cognitive functioning [80][81][82]. The 22 participants included in the analysis received 10 different treatment regimens, ranging anywhere from 4 to 18 cycles.…”

Section: Study Dosingmentioning

confidence: 99%

Nicotinic treatment of post-chemotherapy subjective cognitive impairment: a pilot study

et al. 2019

View full text Add to dashboard Cite

Purpose-Persistent chemotherapy-related cognitive impairment (pCRCI) is commonly reported following cancer treatment and negatively affects quality of life; however, there is currently no pharmacological treatment indicated for pCRCI. This pilot study obtained preliminary data regarding the use of transdermal nicotine patches as a therapeutic strategy for women with pCRCI to(1) reduce subjective cognitive complaints and (2) enhance objective cognitive performance in breast, colon, lymphoma, or ovarian cancer survivors with pCRCI.Methods-Participants were randomized to either placebo (n = 11) or transdermal nicotine (n = 11) for 6 weeks, followed by 2 weeks of treatment withdrawal for a total of 8 weeks. Participants were assessed using both subjective and objective measures of cognitive functioning at five visits before, during, and after treatment.Results-Over the course of the study, women in both groups improved substantially in severity of self-reported cognitive complaints measured by Functional Assessment of Cancer Therapy-Cognitive Function Perceived Cognitive Impairments regardless of treatment arm. Additionally, objective cognitive performance measures improved in both groups; however, there was no significant difference in improvement between groups.

show abstract

Section: Study Dosingmentioning

confidence: 99%

Nicotinic treatment of post-chemotherapy subjective cognitive impairment: a pilot study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Indeed, Ramalho and collaborators showed that there was a significantly increased risk of incident cognitive impairment among patients with schemes including doxorubicin and cyclophosphamide [135]. Moreover, combination regiments, including cyclophosphamide, epirubicin, and 5-FU, had a negative effect on cognition [136].…”

Section: Alkylating Agentsmentioning

confidence: 99%

Cardiovascular and Central Nervous System Toxicity by Anticancer Drugs in Breast Cancer Patients

Natale¹,

Bocci²

2019

Brain and Heart Dynamics

View full text Add to dashboard Cite

“…Since the introduction of paclitaxel to the clinical use in mid-1990's, substantial efforts have been directed to study the adverse effects of this agent (27). Clinical studies and animal models have revealed significant deterioration of cognitive functions shortly after taxane-based chemotherapy (28)(29)(30). Few studies have assessed longitudinal changes of cognitive performance on cancer survivors after taxane therapy.…”

Section: Introductionmentioning

confidence: 99%

Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Purpose: This meta-analysis provides a longitudinal assessment of depression and cognitive impairment induced by taxane-based chemotherapy in women with breast cancer after 6 months of treatment. We highlighted the incidence and prevalence, the cognitive pattern in neuropsychological studies, and the relationship between chemotherapy-induced cognitive impairment and different risk factors. We estimated the effect sizes on each cognitive domain and differentiated effect sizes by each method of comparison of effects (i.e., baseline data, or control groups).Methods: The databases MEDLINE and Embase were searched for publications about taxane-related cognitive changes in patients with breast cancer published from 1980 to 2019. Cross-sectional and self-reported outcomes studies were excluded except for the depression item. Included studies were assessed for risk of bias with the Newcastle–Ottawa Scale. We estimated effect sizes for each cognitive domain and differentiated effect sizes by each method of comparison of effects. The review is reported in compliance with the PRISMA Statement; it was registered prospectively in PROSPERO as CRD42020163255.Results: Eleven studies meeting the criteria were analyzed, which resulted in a sample of 1,057 patients with breast cancer who received chemotherapy including 820 patients (77%) who received taxane-based chemotherapy. Attention and concentration, depression, and executive function domains had significant chemotherapy-induced impairment across all comparison types. Statistically significant improvement was found in language and verbal memory when comparing chemotherapy patients' test scores with baseline or matched controls. Taxane-based chemotherapy had a non-significant effect on processing speed, visual memory, visuospatial, and motor function domains.Conclusions: The occurrence of chemotherapy-induced cognitive impairment 6 months or more after the course of treatment in people with breast cancer is frequent in the domains of attention, executive function, and depression. Other domains appear stable or improve with time after treatment cessation.

show abstract

Role of taxanes in chemotherapy-related cognitive impairment: A prospective longitudinal study

Abstract: Our results suggest that chemotherapy for BC with a FEC regimen can have a negative effect on cognition. Acute deficits seem to be larger when taxanes are added, but treatment seems to affect cognition also at long term.

Cited by 27 publications

References 29 publications

Nicotinic treatment of post-chemotherapy subjective cognitive impairment: a pilot study

Nicotinic treatment of post-chemotherapy subjective cognitive impairment: a pilot study

Cardiovascular and Central Nervous System Toxicity by Anticancer Drugs in Breast Cancer Patients

Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis

Contact Info

Product

Resources

About